{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:53:28Z","timestamp":1790924008704,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Armed Forces Health Surveillance Division, Global Emerging Infections Surveillance (GEIS) Branch"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carbapenem-resistant Gram-negative bacteria (CR-GNB) pose major challenges in intensive care units (ICUs) due to limited treatment options and high mortality. Data describing their predictors in Jordan are scarce. This study aimed to identify risk factors associated with CR-GNB infections among ICU patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted using national surveillance data from 18 ICUs across 13 public hospitals in Jordan between September 2018 and September 2024. Patients with confirmed Gram-negative infections were included. Laboratory testing followed CLSI M100 standards. Logistic regression was performed to determine independent predictors of carbapenem resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1,180 Gram-negative isolates tested, 451 (38%) were carbapenem-resistant.\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      and\n                      <jats:italic>Klebsiella<\/jats:italic>\n                      spp. were the predominant resistant pathogens, while\n                      <jats:italic>E.coli<\/jats:italic>\n                      was mainly carbapenem-susceptible. Independent predictors of carbapenem resistance identified by multivariate logistic regression were: ICU-acquired infection (OR: 2.44; 95% CI: 1.31\u20134.54;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), pneumonia (OR: 2.77; 95% CI: 1.48\u20135.23;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), invasive device use (OR: 3.37; 95% CI: 1.28\u20139.95;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019), and admission to high-risk ICU units (OR: 3.33; 95% CI: 2.06\u20135.48;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Mortality was significantly higher among CR-GNB patients (69.8%) compared to carbapenem-susceptible patients (42.0%), with a 3.15-fold increased risk of death (OR: 3.149; 95% CI: 2.392\u20134.145;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings of this study underscore the need for strategies to prevent and control carbapenem-resistant infections, particularly in high-risk populations such as patients with invasive devices and those diagnosed with pneumonia. Enhanced infection control measures, including strict hand hygiene practices, judicious antibiotic stewardship, and proper management of invasive devices, are essential to minimize the transmission of carbapenem-resistant bacteria in healthcare settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13526-w","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:46:38Z","timestamp":1790426798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors associated with carbapenem-resistant Gram-negative bacterial infections in intensive care units in Jordan"],"prefix":"10.1186","volume":"26","author":[{"given":"Mohammad","family":"Gharaibeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Sayyouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"El-Shokry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwa","family":"Nasrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiam","family":"Khraisat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Alamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Natour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Aljbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Abushawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla\u2019a","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisreen","family":"Migdadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas","family":"Bataienh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Battah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruba","family":"Ikermawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayar","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alhawarat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"issue":"21","key":"13526_CR1","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"JL Vincent","year":"2009","unstructured":"Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323\u20139.","journal-title":"JAMA"},{"key":"13526_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12871-015-0106-9","volume":"15","author":"C Chelazzi","year":"2015","unstructured":"Chelazzi C, Pettini E, Villa G, De Gaudio AR. Epidemiology, associated factors and outcomes of ICU-acquired infections caused by Gram-negative bacteria in critically ill patients: an observational, retrospective study. BMC Anesthesiol. 2015;15:125.","journal-title":"BMC Anesthesiol"},{"key":"13526_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13756-020-00871-x","volume":"10","author":"YR Saharman","year":"2021","unstructured":"Saharman YR, Karuniawati A, Severin JA, Verbrugh HA. Infections and antimicrobial resistance in intensive care units in lower-middle-income countries: a scoping review. Antimicrob Resist Infect Control. 2021;10:22.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"13526_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ijantimicag.2019.07.019","volume":"54","author":"MD Malchione","year":"2019","unstructured":"Malchione MD, Torres LM, Hartley DM, Koch M, Goodman JL. Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: review and mapping of emerging and overlapping challenges. Int J Antimicrob Agents. 2019;54(4):381\u201399.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"13526_CR5","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.3390\/ijms27073115","volume":"27","author":"W Lewandowska","year":"2026","unstructured":"Lewandowska W, Swiecicka I. Perspectives on colistin: an old antibiotic with renewed relevance in modern medicine. Int J Mol Sci. 2026;27(7):3115.","journal-title":"Int J Mol Sci"},{"key":"13526_CR6","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/IDR.S176049","volume":"11","author":"E Davoudi-Monfared","year":"2018","unstructured":"Davoudi-Monfared E, Khalili H. The threat of carbapenem-resistant gram-negative bacteria in a Middle East region. Infect Drug Resist. 2018;11:1831\u201380.","journal-title":"Infect Drug Resist"},{"key":"13526_CR7","unstructured":"AWaRe classification of antibiotics for evaluation and monitoring of use. 2023. Available at: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023. Accessed July 2025."},{"key":"13526_CR8","unstructured":"World Health Organization. WHO bacterial priority pathogens list 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization. 2024. Available at: WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Accessed July 2025."},{"issue":"2","key":"13526_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-0031-1275525","volume":"32","author":"JS Doyle","year":"2011","unstructured":"Doyle JS, Buising KL, Thursky KA, Worth LJ, Richards MJ. Epidemiology of Infections Acquired in Intensive Care Units. Semin Respir Crit Care Med. 2011;32(2):115\u201338.","journal-title":"Semin Respir Crit Care Med"},{"key":"13526_CR10","doi-asserted-by":"publisher","first-page":"8831804","DOI":"10.1155\/2023\/8831804","volume":"2023","author":"M Fadlallah","year":"2023","unstructured":"Fadlallah M, Salman A, Salem-Sokhn E. Updates on the status of carbapenem-resistant Enterobacterales in Lebanon. Int J Microbiol. 2023;2023:8831804.","journal-title":"Int J Microbiol"},{"key":"13526_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jgar.2021.02.033","volume":"25","author":"A Sleiman","year":"2021","unstructured":"Sleiman A, Fayad AGA, Banna H, Matar GM. Prevalence and molecular epidemiology of carbapenem-resistant Gram-negative bacilli and their resistance determinants in the Eastern Mediterranean Region over the last decade. J Glob Antimicrob Resist. 2021;25:209\u201321.","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"13526_CR12","doi-asserted-by":"publisher","first-page":"e00088","DOI":"10.1128\/CMR.00088-17","volume":"31","author":"SR Partridge","year":"2018","unstructured":"Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev. 2018;31(4):e00088\u201317.","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"13526_CR13","first-page":"21","volume":"5","author":"MH Muhammad","year":"2015","unstructured":"Muhammad MH, Swedan S. Molecular and phenotypic characterization of carbapenem resistance and extended-spectrum beta-lactamases among urinary Escherichia coli isolates. Int J Sci Technol. 2015;5(9):21\u20139.","journal-title":"Int J Sci Technol"},{"issue":"8","key":"13526_CR14","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1089\/mdr.2017.0238","volume":"24","author":"AA Aqel","year":"2018","unstructured":"Aqel AA, Findlay J, Al-Maayteh M, Al-Kaabneh A, Hopkins KL, Alzoubi H, et al. Characterization of carbapenemase-producing Enterobacteriaceae from patients in Amman, Jordan. Microb Drug Resist. 2018;24(8):1121\u20137.","journal-title":"Microb Drug Resist"},{"issue":"3","key":"13526_CR15","first-page":"398","volume":"55","author":"S Cetin","year":"2021","unstructured":"Cetin S, Dokmetas I, Hamidi AA, Bayraktar B, Gunduz A, Sevgi DY. Comparison of risk factors and outcomes in carbapenem-resistant and carbapenem-susceptible Gram-negative bacteremia. Sisli Etfal Hastan Tip Bul. 2021;55(3):398\u2013404.","journal-title":"Sisli Etfal Hastan Tip Bul"},{"key":"13526_CR16","unstructured":"Centers for Disease Control and Prevention. National Healthcare Safety Network (NHSN) patient safety component manual [Internet]. Atlanta (GA): Centers for Disease Control and Prevention. 2026 Jan [accessed on April 16\/2026]. Available from: https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/pscmanual_current.pdf"},{"key":"13526_CR17","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100. 28th-34th eds. 2018\u20132024."},{"issue":"8","key":"13526_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1473-3099(05)70189-4","volume":"5","author":"IN Okeke","year":"2005","unstructured":"Okeke IN, Laxminarayan R, Bhutta ZA, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis. 2005;5(8):481\u201393.","journal-title":"Lancet Infect Dis"},{"key":"13526_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1586\/14787210.2014.902306","volume":"12","author":"AY Guh","year":"2014","unstructured":"Guh AY, Limbago BM, Kallen AJ. Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States. Expert Rev Anti Infect Ther. 2014;12:565\u201380.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"13526_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1186\/s12879-023-08610-4","volume":"23","author":"KA Hammour","year":"2023","unstructured":"Hammour KA, Abu-Farha R, Itani R, Karout S, Allan A, Manaseer Q, Hammour WA. The prevalence of carbapenem-resistant Gram-negative pathogens in a tertiary teaching hospital in Jordan. BMC Infect Dis. 2023;23(1):634.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"13526_CR21","first-page":"15","volume":"3","author":"G Meletis","year":"2016","unstructured":"Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15\u201321.","journal-title":"Ther Adv Infect Dis"},{"key":"13526_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2150132720961255","volume":"11","author":"DH Abdel-Qader","year":"2020","unstructured":"Abdel-Qader DH, Albassam A, Ismael NS, El-Shara\u2019 AA, Shehri A, Almutairi FS, Al-Harbi DM, Al Zahrani MM, Chen LC, Al Mazrouei N, Ibrahim OM. Awareness of antibiotic use and resistance in the Jordanian community. J Prim Care Community Health. 2020;11:1\u20138.","journal-title":"J Prim Care Community Health"},{"issue":"9","key":"13526_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1473-3099(05)70217-6","volume":"5","author":"IN Okeke","year":"2005","unstructured":"Okeke IN, Klugman KP, Bhutta ZA, et al. Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis. 2005;5(9):568\u201380.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"13526_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/microorganisms10050849","volume":"10","author":"M Al-Tamimi","year":"2022","unstructured":"Al-Tamimi M, Albalawi H, Alkhawaldeh M, Alazzam A, Ramadan H, Altalalwah M, et al. Multidrug-resistant Acinetobacter baumannii in Jordan. Microorganisms. 2022;10(5):849.","journal-title":"Microorganisms"},{"key":"13526_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1128\/CMR.00096-12","volume":"26","author":"HM Zowawi","year":"2013","unstructured":"Zowawi HM, Balkhy HH, Walsh TR, Paterson DL. \u03b2-lactamase production in key Gram-negative pathogen isolates from the Arabian Peninsula. Clin Microbiol Rev. 2013;26:361\u201380.","journal-title":"Clin Microbiol Rev"},{"key":"13526_CR26","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/529198","volume":"46","author":"LL Maragakis","year":"2008","unstructured":"Maragakis LL, Perl TM. Antimicrobial resistance: Acinetobacter baumannii\u2014epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46:1254\u201363.","journal-title":"Clin Infect Dis"},{"key":"13526_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/iub.532","volume":"63","author":"L Poirel","year":"2011","unstructured":"Poirel L, Bonnin RA, Nordmann P. Genetic basis of antibiotic resistance in pathogenic Acinetobacter species. IUBMB Life. 2011;63:1061\u20137.","journal-title":"IUBMB Life"},{"issue":"6","key":"13526_CR28","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.12998\/wjcc.v10.i6.1795","volume":"10","author":"Y Han","year":"2022","unstructured":"Han Y, Zhang J, Zhang HZ, Zhang XY, Wang YM. Multidrug-resistant organisms in intensive care units and logistic analysis of risk factors. World J Clin Cases. 2022;10(6):1795\u2013805.","journal-title":"World J Clin Cases"},{"issue":"3","key":"13526_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4103\/0974-777X.68538","volume":"2","author":"V Manchanda","year":"2010","unstructured":"Manchanda V, Sanchaita S, Singh N. Multidrug-resistant Acinetobacter. J Glob Infect Dis. 2010;2(3):291\u2013304.","journal-title":"J Glob Infect Dis"},{"issue":"Suppl 4","key":"13526_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0213-005X(14)70173-9","volume":"32","author":"PJ Pano","year":"2014","unstructured":"Pano PJ, Serrano VS, Ramos RJ, Pintado V. Infections caused by carbapenemase-producing Enterobacteriaceae: risk factors, clinical features, and prognosis. Enferm Infecc Microbiol Clin. 2014;32(Suppl 4):41\u20138.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"13526_CR31","doi-asserted-by":"publisher","first-page":"894341","DOI":"10.3389\/fmicb.2022.894341","volume":"13","author":"B Guo","year":"2022","unstructured":"Guo B, Guo Z, Zhang H, Shi C, Qin B, Wang S, et al. Prevalence and risk factors of carbapenem-resistant Enterobacterales positivity by active screening in intensive care units in the Henan Province of China: a multicenter cross-sectional study. Front Microbiol. 2022;13:894341.","journal-title":"Front Microbiol"},{"issue":"6","key":"13526_CR32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/14787210.2016.1177457","volume":"14","author":"R Ozaras","year":"2016","unstructured":"Ozaras R, Leblebicioglu H, Sunbul M, Tabak F, Balkan II, Yemisen M, et al. The Syrian conflict and infectious diseases. Expert Rev Anti Infect Ther. 2016;14(6):547\u201355.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"13526_CR33","first-page":"25","volume":"17","author":"L Yang","year":"2020","unstructured":"Yang L, Li SQ, Li QR, Yang X, Li YX. Analysis of susceptibility and prognostic factors for carbapenem-resistant Enterobacteriaceae in ICU patients. Lab Med Clin. 2020;17:25\u201330.","journal-title":"Lab Med Clin"},{"key":"13526_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jgar.2022.04.005","volume":"30","author":"Y Gao","year":"2022","unstructured":"Gao Y, Chen M, Cai M, Liu K, Wang Y, Zhou C, Chang Z, Zou Q, Xiao S, Cao Y, Wang W, Liu Z, Lv L, Luo Y. Yinghong. An analysis of risk factors for carbapenem-resistant Enterobacteriaceae infection. J Glob Antimicrob Resist. 2022;30:191\u20138.","journal-title":"J Glob Antimicrob Resist"},{"key":"13526_CR35","first-page":"15","volume":"21","author":"Q Li","year":"2019","unstructured":"Li Q, Guo LJ, Wang YJ, Guo W, Deng YL, Dai XG. Multivariate analysis of carbapenem-resistant Enterobacteriaceae infection in intensive care units. J Xiangnan Univ Med Sci. 2019;21:15\u20139.","journal-title":"J Xiangnan Univ Med Sci"},{"issue":"3","key":"13526_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/cc5911","volume":"11","author":"ME Falagas","year":"2007","unstructured":"Falagas ME, Rafailidis PI. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care. 2007;11(3):134.","journal-title":"Crit Care"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13526-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13526-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13526-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:01:46Z","timestamp":1790920906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13526-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13526"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13526-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol # NAMRU3.PJT.2011.0014 was reviewed and approved by the Naval Medical Research Command Institutional Review Board in compliance with all applicable Federal regulations governing the protection of human subjects (including declaration of Helsinki). The board declared the study as an activity not involving human research which does not required consent (i.e. waiver of consent).","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.S. is an employee of the U.S. Government. This work was prepared as part of her official duties. Title 17, U.S.C. \u00a7 105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, U.S.C. \u00a7 101 defines a U.S. Government work as work prepared by a military service member or employee of the U.S. Government as part of that person\u2019s official duties.","order":3,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1756"}}